Crystal Bowersox, a northwest Ohio native currently calling Nashville, TN home, has built her life around music. Since her introduction to the world, Crystal has released 3 LP’s, two EPs, several singles, and is currently developing an autobiographical, theatrical rock concert titled, “Trauma Queen”.
In July of 2020, Crystal released the first long awaited single from her upcoming album, HitchHiker, to be released in 2021. The first single, Courage to Be Kind, was written in 2017 with accomplished songwriter and personal hero to Crystal, Steve Seskin. In the folk, rock gospel anthem, Crystal’s voice soars as she tackles several controversial topics. “It takes Courage to be kind / To be brave enough to walk your love across a party line.”
She has used her voice and talents to benefit several causes close to her heart, and has become an inspiration and advocate for people living with Type 1 Diabetes.
Women Fitness is honored to have Talented Crystal Bowersox to talk about her journey with music & type 1 diabetes to inspire people towards healthy living.
Your love for music developed at an incredibly early age which finally led to the release of your debut album, “Farmer’s Daughter” on Jive Records. Share your journey with music to become runner-up on the ninth season of American Idol.
I started playing music and performing around the age of 10 in my hometown. I was 24 years old when I finished second on American Idol. I believe my musical journey is just beginning. I will be releasing my fourth full length album soon, and as I have grown, so has my music.
You were diagnosed with type 1 diabetes at the age of 6. How did you do about balancing school, passion for music and diabetes treatment?
Balancing a touring career, single-motherhood, and diabetes can certainly be a challenge. However, I strive to do my best every single day to set a good example for my eleven-year-old son. I want him to grow up knowing that no matter what challenges you face, you can achieve your dreams and goals through determination and self-discipline.
Disclaimer The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The House Judiciary Committee Antitrust Subcommittee’s majority staff report on antitrust takes aim at now-Seventh Circuit Judge Frank Easterbrook’s seminal law review article The Limits of Antitrust. In that article, Judge Easterbrook explained the risks with overenforcement of antitrust law. Because of these risks, he urged erring on the side of caution. In statistical terms, he advocated avoiding Type I errors. Today, Judge Easterbrook’s position is considered mainstream.
Yet the report suggests Congress repudiate Judge Easterbrook’s position. As an alternative, the report urges Congress to say that cautious antitrust enforcement is as harmful as overenforcement. Congress should reject this plea because Judge Easterbrook was right. The Department of Justice, the Federal Trade Commission, and courts should continue to recognize that “antitrust is an imperfect tool for the regulation of competition.” Since it is an imperfect science, we should strive to avoid Type I errors.
In the real world, judges and policymakers lack perfect information about markets, competitors, and consumers. Without perfect information, it is impossible to flawlessly enforce antitrust laws. Rather, enforcement agencies make mistakes. Sometimes, a business will get away with anticompetitive behavior because of this imperfect information. Other times, a company will get sanctioned because of pro-competitive behavior. Unless we live in the House Judiciary Committee’s fantasyland, avoiding errors in antitrust enforcement is impossible. The question is which mistakes do we want to avoid? Or should we be indifferent to the types of errors we make?
The answer is clear: As Judge Easterbrook said, we should err on the side of caution. There are several reasons why this is the best approach:
Violating the antitrust laws can lead to more than just civil liability: It also carries criminal penalties. As Benjamin Franklin said, “it is better 100 guilty Persons should escape, than that one innocent Person should suffer.” But if antitrust laws are enforced in the manner suggested by the majority staff, there will be one innocent executive thrown in prison for every one executive that escapes antitrust liability. This goes against well-settled due process principles.
Successful plaintiffs in antitrust suits are entitled to treble (triple) damages. They also get attorneys’ fees and costs. From an economic perspective, this means that—ignoring possible criminal liability—companies will not engage in anti-competitive behavior if the risk of getting caught is higher than about 30%. This is enough to deter companies from engaging in most anti-competitive behavior.
Because treble damages—combined with the current level of enforcement—can deter anti-competitive behavior, increasing enforcement will lead to companies shying away from pro-competitive behavior. Even if a company knows that its actions fully comply with antitrust laws, it may decide against engaging in those actions because of the risk of erroneous enforcement activity. In other words, the benefits that the company sees from the pro-competitive behavior may be outweighed by the risk of the company being improperly found to have violated antitrust laws. This risk is especially troubling because firms do not internalize consumer benefits to their pro-competitive conduct. So although the total welfare increase may dwarf the costs of an erroneous antitrust enforcement action, companies care about only that portion the companies realize. This further distorts the market and keeps innovation at bay in the name of political expediency.
The damage from cautious antitrust enforcement is relatively low. The market destroys a monopoly. When other firms see monopoly profits, they enter the market. Eventually, this eliminates monopoly rents. Antitrust enforcement merely speeds up the process of a return to competitive markets.
These reasons do not include the focus of Judge Easterbrook’s article. He explained that the nation’s best economists can disagree about the effect of some competitive activities. The disagreement could stem from different assumptions or different methodologies. Without a crystal ball and perfect knowledge about all firms, it is impossible for Nobel-prize-winning economists to agree on whether actions help or hurt competition.
If the best economists in the world cannot agree, what chance is there for generalist federal judges and lay jurors? The answer is obvious—none. In many cases, a judge or jury might as well flip a coin to decide whether to hold a company liable. They lack the education and training to understand the theoretical underpinnings of a case. They similarly lack the mathematical background to process the complex econometric analysis that is the staple of today’s antitrust litigation.
The House Judiciary Committee Antitrust Subcommittee’s majority staff report is an anti-capitalist manifesto. The attack on Judge Easterbrook is meant to undermine the Chicago School of Economics. Those pushing for more antitrust enforcement want legal victories that they can use to then push for more anti-capitalist reforms.
It seeks to destroy entrepreneurial businesses that contribute to Americans’ well-being. The report would prefer companies like Google and Amazon—which have become indispensable during the COVID-19 pandemic—disappear. The subcommittee staff opposes these successful businesses because they recognize the companies are free-market success stories that benefit society.
The report tries to disguise the attack by dressing it up as antitrust law. Yet it lacks any basis in law or economic reality. It therefore should be seen for what it is—a full-frontal attack on our market-based economy. Courts and governmental regulators must reject it as pure propaganda.
The Australian Red Cross has faced yet another medical dilemma as the country faces a shortage of two of the most common blood types. All blood plasma types are needed, Lifeblood’s supplies of O+ and A+ blood are running low in particular.
It has been two days since the supply has been down, and to date, there are 16,000 people needed to replenish stocks within two weeks.
This deficit in supply has been greatly affected by the pandemic with fewer donors making appointments, thus, the service is in need of an urgent call.
Around 1,200 people every day are either cancelling their appointments or do not turn up to their donations.
Lifeblood Executive Director Cath Stone revealed “As restrictions return in South Australia, and are eased in other parts of the country, it’s essential that blood and plasma donations continue.”
Considering the statistics, 31,000 donations are needed on a weekly basis to help patients in times of trauma, major surgery, cancer treatment, pregnancy and numerous other medical necessities.
The service saw the absolute best of the community throughout the pandemic as donors are continuing to make appointments and appear despite virus threats. However, these donations are not sufficient as the decrease of donor came to surge.
Provided that around 71 per cent of Australia’s population has an O+ or A+ blood type, it is safe to say that the blood donors can be of a huge help for the patients in need. As Ms. Stone emphasized, the need for blood “never stops”.
“We urge those who can to make blood or plasma donation part of their ‘new normal’,” she added. “Even if you don’t know what blood type you have, we still need you – we need all blood types every day.”
The service assured that they have increased rigorous wellness checks prior to donation appointments, including temperature checking, to ensure the health and safety of the donors.
Wanting to book a blood and plasma donation? Visit lifeblood.com.au or call 13 14 95
A NOTE ABOUT RELEVANT ADVERTISING: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. This is also known as Online Behavioural Advertising. You can find out more about our policy and your choices, including how to opt-out here.
Here’s What You Need To Remember: The Kalashnikov-inspired rifle is a remarkable piece of engineering, combining the Soviet design with a new firing mechanism and several other innovations.
In the 1980s, China’s small arms were largely inferior to the United States and Russia. The PLA was mostly armed with the Type 56 assault rifle, a clone of the original AK-47, and the Type 56 carbine, a clone of the Soviet SKS. There was an abortive attempt to combine the characteristics of these rifles in the 1960s which culminated in the Type 63, an SKS-looking select-fire rifle that used elements of the AK operating mechanism such as a rotating bolt and fed from AK magazines. The Type 63 was too heavy and lacked a pistol grip and inline stock to afford controllability in fully automatic fire. It was an outdated rifle when it was introduced, especially compared to the American M16 and Soviet AKM. The PLA realized this and began development of a new 5.8mm caliber the rifles for it, which eventually became the QBZ-95. However a “stopgap” rifle was needed, to quickly replace the Type 56 AKs. From this requirement, the Type 81 was born.
The Type 81 was not meant to be just a rifle. It was meant to be a test of the Chinese ability to develop small arms on its own, instead of simply adapting other designs. Unlike the Type 63 carbine before it, the Type 81 used a gas system of purely Chinese design. It also addressed flaws of the earlier rifles in light of combat experience in the Sino-Vietnamese war. In an attempt to make the rifles more modular and adaptable, the integral folding bayonet of the Type 56s and Type 63 was scrapped in favor of a removable knife bayonet and the provision to mount an underslung grenade launcher. The barrel was also lengthened and given a spigot to allow the Type 81 to launch rifle grenades. It also featured a novel sighting system, ditching the AK and SKS rear leaf sights in favor of a shielded aperture that resembled the early M16s. The earlier Type 56 assault rifle was also considered to have too poor accuracy in single fire mode (oddly, contrary to the Soviet experience in the 1950s). This flaw was also in the minds of Chinese designers, who specifically designed the Type 81 to be more accurate than the Type 56, utilizing a short-stroke gas piston system as opposed to the long-stroke used in the Type 56. The barrel manufacturing techniques were also improved, and the barrel itself is longer relative to the Type 56 assault rifle.
The end result was an impressive fusion of designs. The Type 81 was reliable, able to shoot around 15,000 rounds on average without parts breaking or needing replacement. It was more accurate than a standard AK in 7.62×39, with less recoil. The provision for soldiers to launch grenades two different ways was added. Apart from some early issues such as the sight zero being thrown off by launching rifle grenades, the Type 81 was loved by the soldiers who were issued it. It saw its first action in the Sino-Vietnamese border conflicts.
Despite its success, in the end, the Type 81 was still a stopgap rifle. What the PLA really wanted was a rifle in a new true intermediate caliber: 5.8mm. As this caliber started to reach maturity, some versions of the Type 81 were chambered in it as testbeds for the new caliber. It was eventually replaced in frontline PLA service by the QBZ-95. That wasn’t the end of the road for the Type 81 though. It continues to see service in the People’s Armed Police, upgraded with Picatinny rails that allow it to mount modern optics, and has proven to be an adaptable design. When a new series of Chinese DMRs were revealed around 2015, they too were derivatives of the Type 81 design, despite the new name of CS/LR-14. These new DMRs are the Chinese answer to compete with other 7.62 DMR rifles such as the FN SCAR and SR-25 on the global export market. China’s 1980s stopgap rifle may continue to see service far into the twenty-first century.
Charlie Gao studied political and computer science at Grinnell College and is a frequent commentator on defense and national-security issues. This article first appeared in 2018.
Living A Full, Vibrant Life With A Type 1 Diabetes Diet : People with Type 1 diabetes are constantly looking for new ways to improve their lives. Whether it be an improved exercise regimen or a healthier diet, these individuals struggle daily to control their blood glucose levels. There is no doubt that options are available.
But, many of these options come with a lot of fluff. Some even guarantee cures but fail miserably. If you are a diabetic or know someone who is, you know there are lots of snake oil salesmen on the World Wide Web making false cure promises.
With this said, one of the best options you will ever come across is a Type I diabetic diet. What does this entail? Find the answer in the article below.
Minimize Your Insulin Need
Like most people, diabetics like to mix up their diets from one day to the next. While this works great for healthy people, diabetics must monitor their diet carefully. They must avoid consuming too many carbohydrates, including sugar, dietary fiber, and starches. All of these foods are known for having negative effects on blood glucose levels.
While oatmeal contains carbohydrates, it has been deemed safe for people with diabetes. One cup of prepared oatmeal has about 30 grams of carbohydrates. This is the ideal amount to add to a new diabetic diet plan.
Cooked oatmeal is believed to help improve blood sugar levels by minimizing insulin needs. What this means is pure, cooked oatmeal might decrease your insulin need. If you eat oatmeal regularly, you could very well reduce your insulin dose. But, only under the supervision of a medical professional.
Staying On Track
Many medical experts describe lentils as “smart legumes” because they contain a mixture of insoluble and soluble dietary fiber. Both forms of dietary fiber bypass the system and go directly to the intestines where it binds with cholesterol. For this reason, insoluble dietary fiber is believed to help diabetics manage their blood glucose levels better.
Lentils are ranked as “low glycemic index” foods, which means they may reduce blood glucose levels when eaten regularly. Medical professionals recommend lentils to their diabetic patients because they can help prevent increasing blood glucose levels.
If you are struggling to maintain optimal blood sugar levels, you should definitely consider incorporating lentils into your diabetic diet. If you decide to go this route, you should speak with your primary care physician in advance. Your physician will recommend close monitoring of your blood glucose level to determine the effectiveness of the oatmeal. Those who are not covered under a health care insurance policy should purchase Canadian insulin, which is available at a fraction of American prices.
Rich In Omega-3 Fatty Acids
Type 1 diabetes has been linked to inflammation. In fact, some medical experts believe inflammation leads to Type I diabetes when the cells responsible for producing insulin are damaged. Regardless of the cause, your diabetes diagnosis has taken a toll on your body.
Fish and other foods rich in omega-3 fatty acids contain properties that fight against inflammation. Not only is it believed that these fatty acids can improve your blood glucose levels but they also may reduce the risks of diabetes.
Children with a family history of diabetes should eat the recommended amount of omega-3 fatty acids. Seafood, such as fish, oysters, tofu, and sardines contain omega-3 fatty acids.
Stay Hydrated While Managing Your Blood Glucose Levels
Most diabetics will agree that managing blood sugar levels is an extremely difficult, ongoing task. With this said, diabetics who drink the recommended amount of water daily find this task easier. While there is no way to make your Type I diabetes go away, water can minimize your blood glucose management effort. How is this possible?
Well, first of all, water is believed to flush excess glucose out of the system through the kidneys. By removing excess glucose from your body, you will find it much easier to maintain optimal blood sugar levels.
The recommended amount of water for women with diabetes to consume at least nine cups of water per day. Diabetic males, on the other hand, should consume four additional cups of water each day. In total, diabetic males should consume 3 liters and diabetic females 2.2 liters of water daily.
Related Videos about Living A Full, Vibrant Life With A Type 1 Diabetes Diet :
A Message to My Team: Eating Healthy with Type 1 Diabetes
Type 1 Diabetes and Food: What School Staff Should Know
Type 1 Diabetes Diet
Type 1 Diabetes & Food – What I Eat
What Food Can Type 1 Diabetes Eat | Diabetic Diet
Living A Full, Vibrant Life With A Type 1 Diabetes Diet
type 1 diabetes foods to avoid, diabetes type 1 diet and exercise, type 1 diabetes, skipping meals, type 1 diabetes meal ideas, type 1 diabetes meal plan pdf, fruits for type 1 diabetes, type 1 diabetes diet for child, best diet for type 1 diabetes to lose weight,
It can happen in a New York minute. We are talking about the massive gains certain healthcare stocks are able to notch in what feels like a split second. Unlike names from other areas of the market, earnings results don’t paint the full picture. Rather, other factors like clinical trial data or regulatory decisions can be more useful in determining if a particular company is on the path to life-sustaining revenues. Therefore, any positive update can be the catalyst that sends shares blasting off towards outer space.These plays, however, aren’t without their risk. A disappointing outcome could also be the spark that ignites the flame, only launching shares in the opposite direction. This is what makes compelling healthcare stocks so difficult to spot, but the analysts can help.Using TipRanks’ database, we found three healthcare stocks getting love from the Street ahead of major possible catalysts. Each name has amassed enough bullish calls to earn a “Strong Buy” consensus rating. Hefty upside potential is also on the table here.Kala Pharmaceuticals (KALA)Developing treatments for inflammatory ocular conditions, Kala Pharmaceuticals wants to improve the lives of patients everywhere. With the October 30 PDUFA date for its EYSUVIS product fast-approaching, several analysts think that now is the time to get on board.EYSUVIS is a corticosteroid designed for the short-term treatment of signs and symptoms of dry eye disease (DED). DED is a multifactorial disease of the tears and ocular surface of the eye that causes discomfort, visual disturbances and tear film instability, which is usually accompanied by hyperosmolarity (higher concentration of salt than water in tears) and inflammation. Affecting about 16.4 million adults in the U.S., the condition has a major impact on a patient’s quality of life, and in some cases, can lead to declines in work productivity.Wedbush analyst Liana Moussatos is optimistic about the therapy’s prospects, noting that approval could come before the PDUFA date. To this end, a U.S. launch is forecasted for early 2021, with KALA set to be launch ready in Q4 2020, and the analyst believes blockbuster revenue ($1 billion) could be in store.Citing presentations from Key Opinion Leaders (KOLs), Moussatos highlights the broad market opportunity for the asset given the current unmet need and its potential position as the first approved corticosteroid in this indication.Additionally, based on clinical data, unlike already approved drugs RESTASIS, CEQUA and XIIDRA, the therapy generated a rapid onset of action, with it also overcoming well-known adverse events associated with ketosteroids such as increases in intraocular pressure (IOP).Moussatos mentioned, “Dr. Holland made specific reference in his remarks to both EYSUVIS’ rapid onset of action as well as its favorable safety profile with respect to IOP elevation as reason for his choice to use it as first-line therapy for a high percentage of his patients if approved.”Summing it all up, the analyst stated, “Given the inadequate control of dry eye flares on current standard-of-care treatments and the unwillingness of eye care professionals (except cornea specialists) to use corticosteroids off-label, we feel EYSUVIS is uniquely positioned to immediately address an underserved portion of the market using corticosteroids off-label as a short-term therapy for rapid relief while gradually addressing chronic users of immunomodulatory agents such as cyclosporine (RESTASIS, CEQUA) and lifitegrast (XIIDRA) on maintenance therapy.”To this end, Moussatos rates KALA an Outperform (i.e. Buy) along with a $39 price target. This puts the upside potential at a massive 430%. (To watch Moussatos’ track record, click here)In general, other analysts echo Moussatos’ sentiment. 4 Buys and 1 Hold add up to a Strong Buy consensus rating. With an average price target of $20.80, the upside potential comes in at 173%. (See KALA stock analysis on TipRanks)Revance Therapeutics (RVNC)Focused on innovative aesthetic and therapeutic offerings, Revance Therapeutics works to address the unmet needs of patients. As multiple catalysts are on the horizon, Wall Street is pounding the table.Investors are eagerly awaiting the FDA decision regarding RVNC’s novel botulinum toxin (BoNT) product, daxibotulinumtoxinA for Injection (DAXI), in glabellar (frown) lines. The PDUFA date is scheduled for November 25.Ahead of the decision, Guggenheim’s Seamus Fernandez has high hopes. “Given the positive SAKURA results, our approval expectations are high,” the 5-star analyst commented.That being said, Fernandez argues “DAXI’s potential in the therapeutic market is underappreciated, particularly for the upcoming ASPEN-1 results in cervical dystonia (CD),” which is a movement disorder that results in abnormal posture or twisting of the neck. This indication marks DAXI’s foray into the world of therapeutics, with the pivotal ASPEN-1 top-line data readout set to come by or before late-November. When it comes to DAXI in the CD indication, the asset’s long-acting profile makes it a stand-out compared to available BoNTs, which are short-acting. In a Phase 2 trial, DAXI demonstrated a duration of effect greater than 20-24 weeks at all doses, versus that of marketed BoNT toxins (12 weeks on average; ranges 12-18 weeks depending on the formulation or dose).“Payers have limited BoNT access to an every-12-week (Q12W) dosing schedule for CD. However, based on expert discussions, 20-25% of de novo CD patients complain of pain recurring prior to the next injection, and thus do not find relief from the existing insurance-mandated Q12W dosing schedule. DAXI could be an alternative BoNT for these patients. Moreover, DAXI had demonstrated a peak treatment effect of 50% in its earlier Phase 2 trial, which, in our view, is best-in-class,” Fernandez explained. To this end, substantial upside could be in the cards if RVNC reports positive data.If that wasn’t enough, the release of top-line results from its Phase 2 trial in plantar fasciitis (PF), a common cause of heel pain, is slated for the same timeframe. Roughly 2 million patients with the condition seek treatment annually, but the standard-of-care usually includes NSAIDs, orthotics, physical therapy, rest, weight loss or corticosteroids, with physicians trying to avoid excessive use of steroids.However, BoNTs, used off-label by some specialists due to success in small studies, have yet to succeed in a randomized Phase 2 or Phase 3 study. “Given the opportunity to differentiate itself from the existing BoNT therapeutic market, RVNC is conducting a second larger Phase 2 trial with 155 patients,” Fernandez noted. While his models don’t include PF, favorable results could be a game changer.Taking all of this into consideration, Fernandez maintains a Buy rating and $41 price target. This target conveys his confidence in RVNC’s ability to climb 65% higher in the next year. (To watch Fernandez’s track record, click here)Are other analysts in agreement? They are. Only Buy ratings, 5 to be exact, have been issued in the last three months. Therefore, the message is clear: RVNC is a Strong Buy. Given the $34.20 average price target, shares could surge 38% in the next year. (See RVNC stock analysis on TipRanks)Rhythm Pharmaceuticals (RYTM)Changing the way rare genetic disorders of obesity are diagnosed and treated, Rhythm Pharmaceuticals is developing cutting-edge therapies. As it gears up for key potential catalysts, the Street has its eye on this healthcare name.Back in May, the FDA accepted RYTM’s new drug application for setmelanotide, the company’s melanocortin-4 receptor (MC4R) agonist, in pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency obesities. With a PDUFA date set for November 22, an approval decision is right around the corner.Ladenburg analyst Michael Higgins points out that after an update from management, his bullish thesis remains very much intact.RYTM revealed that once weekly dosing of setmelanotide achieved similar results to the daily formulation, with comparable weight loss among treated patients exceeding placebo. “This data could set up a label expansion for setmelanotide following approval and may be particularly advantageous for pediatric administration, who are often most afflicted by POMC and LEPR,” Higgins commented.The analyst is also watching out for data from the pivotal trial evaluating setmelanotide in Bardet-Biedl Syndrome (BBS) and Alström syndrome, with data expected in Q4 2020 or Q1 2021, and the Phase 2 Basket Study of setmelanotide in high-impact heterozygous (HET) obesity and other genetic disorders, which could be released in Q4 2020.In a recent journal article highlighting setmelanotide in BBS patients, the published data further highlights the success of BBS patients who are taking setmelanotide, as efficacy measures increase with prolonged use. Higgins sees the article as encouraging, given that it was written by several reputable KOLs.Higgins points out that this pivotal patient data set is at least twice the size of the POMC/LEPR Phase 3 trial, conveying the increase in the size of the market opportunity. There are roughly 250 POMC/LEPR patients in the U.S., compared to approximately 2,000 BBS/Alström patients. As for the basket study, Higgins estimates there are tens of thousands of patients with MCR pathway disorders.Given all of the above, Higgins stays with the bulls. In addition to a Buy rating, he puts a $43 price target on the stock. Investors could be pocketing a gain of 95%, should this target be met in the twelve months ahead. (To watch Higgins’ track record, click here)Judging by the consensus breakdown, opinions are anything but mixed. With 4 Buys and no Holds or Sells assigned in the last three months, the word on the Street is that RYTM is a Strong Buy. At $38.67, the average price target implies 75% upside potential. (See RYTM stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Before his death three years ago, Chinese activist Liu Xiaobo left this message for those who would challenge China’s communist one-party rule: “I have no enemies and no hatred.” To counter the regime’s hostility toward freedom and democracy, said the Nobel Peace Prize laureate, one must “dispel hatred with love.” An echo of his approach is now playing out among one of China’s ethnic minorities, some 4.2 million Mongolians living in the northern region of Inner Mongolia.
This week, an edict from Beijing required Mongolian schoolchildren to stop using their native language in half of their classes. Instead they would be forced to learn in Mandarin, the official national language of China’s ethnic Han majority. A similar draconian effort to impose Han culture – and also official party dogma – already began against the Uyghur Muslims in Xinjiang province in 2017 and the Buddhists of Tibet in 2018.
While some Mongolians protested in the streets – invoking the legend of Genghis Khan with chants like “Mongolian brothers, get on your horses!” – others did something almost unheard-of. An estimated 300,000 students did not go to school, leaving classrooms largely empty. Many teachers also joined the rare boycott, offering to teach children in their homes – in Mongolian. A few high school students began a hunger strike.
Many Mongolian police who have school-age children refused to go to work so as not to participate in the official crackdown. “I want to live by my principles,” one policeman told the Los Angeles Times.
Get the Monitor Stories you care about delivered to your inbox.
The more that the country’s hard-line leader Xi Jinping tries to impose his harsh rule, the more the tactics of dissent in China may be shifting toward Mr. Liu’s approach. In Hong Kong, for example, many pro-democracy activists are asserting their rights in creative ways, such as expressing songs without lyrics or holding up posters without words. The meaning is clear to the millions in Hong Kong who reject authoritarian rule and the imposition of the mainland’s Han culture.
In 1989, during the pro-democracy protests in Beijing’s Tiananmen Square, the use of nonviolent tactics was symbolized by the famous image of a lone man blocking a column of tanks. Today, many in China are searching for ways that express protest of state violence without hatred. The threat of state violence is designed to establish a prison in the thinking of people in China. Breaking out of that prison requires a courageous step away from both hate and fear.
Understanding Type 2 Diabetes Symptoms and Their Effect on Men’s Health
August 2, 2020
Men, by and large, are at a
higher risk for various adverse health outcomes compared to their female
counterparts, especially when it comes to some of the top leading causes of
death in the U.S., such as diabetes. While diabetes affects over 30 million people
in the nation, men, biologically speaking, have a higher susceptibility to
being diagnosed with type 2 diabetes, which accounts for 95% of all diagnosed
diabetes cases. Fortunately, with preventative measures and proper health
management, men can reduce their risk of developing diabetes, and the negative
health outcomes brought about by the disease. Here are a few tips to start:
Learn the Signs and Symptoms of Diabetes Specific to Men’s Health
Although men have a greater
predisposition to type 2 diabetes, they are still at risk for other forms of
diabetes like type 1. With both type 1 and type 2
symptoms may appear gradually or, in some cases, not at all. But more than
likely, diabetes will manifest itself in one or more of the following signs:
Both men and women share
some of the tell-tale signs of diabetes. However, men may also experience
unique effects of diabetes pertaining to urological and sexual health, such as:
The inability to achieve or maintain an erection, known as erectile dysfunction
(ED), will affect a large majority of men over the course of their lifetime.
But it is estimated that men who have diabetes will
develop ED up
to 15 years earlier than non-diabetic men. This is likely because uncontrolled
high blood sugar can damage the blood vessels and nerves in the penis.
thrush: Thrush is a type of yeast
infection common in individuals with diabetes because the high glucose levels
in the body provide an optimal breeding ground for fungus. In men, genital
thrust typically affects the head of the penis resulting in redness, swelling,
itching, in addition to cottage-cheese like discharge under the foreskin and
damage from diabetes can affect how a male’s bladder contracts during
ejaculation, causing semen to travel back up into the bladder rather than out
through the penis.
It’s important for men to
recognize the indications and characteristics of diabetes to receive a timely
and proper diagnosis and prevent further diabetes-related
Understand the Risk Factors of Diabetes for Men
We know that gender in and
of itself is a significant risk factor for men when it comes to developing type
2 diabetes specifically. But other risk factors, modifiable and non-modifiable,
that can increase the likelihood of men developing diabetes include:
Being physically inactive less than three
times a week
Eating a poor diet; high in sugar and
Having an ethnic background of
African-American, Hispanic, American Indian, Native Alaskan, Asian American,
and Pacific Islander
Improve Your Health to Prevent or Manage Diabetes
Whether you are at risk of
developing diabetes or have already been diagnosed with diabetes, it’s never
too late to make changes to your lifestyle that will improve your health and
prognosis. The first step is to talk to your doctor, as they can perform a
blood glucose test that can help detect type 2 diabetes and guide you toward
any medication or other treatments you may need. However, there are steps men
should take on their own as well to help mitigate diabetes risk and
Avoid unhealthy habits like smoking and
excessive drinking; ideally, men should have no more than two drinks a day
Aim for an active lifestyle consisting of
at least 30 minutes of exercise per day
Eat a balanced diet to control your blood
sugar levels; avoid added sugar, sodium, and fats (“good fats” like avocados
and nuts are okay), and strive for fruits, vegetables, and whole grains high in